The dual expression of VEGFR/VEGF-A in ovarian cancer, as well as in other types of cancers, suggests that the activation of tumour cell signalling pathways by VEGF-A might be an autocrine mechanism that could also be present in other tumours such as colorectal or breast carcinoma (Masood et al, 2001; Price et al, 2001; Chen et al, 2004; Fan et al, 2005; Wedam et al, 2006). Here, VEGFA is linked to breast carcinoma.